MET Plus CBT for Ecstasy Use When Clients Are Depressed: A Case Series

Cognitive and Behavioral Practice

Volumn 21, Issue 1, 2014, Pages 55-63

  Norberg, Melissa M ^a   Perry, Ursula ^a   Mackenzie, Jennifer ^a   Copeland, Jan ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cognitive behaviour therapy; Ecstasy; MDMA; Motivational enhancement therapy; Motivational interviewing

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; OXYCODONE;

ADULT; ALCOHOLISM; ANXIETY; ARTICLE; CANNABIS USE; CASE REPORT; CASE STUDY; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DEPRESSION; DEPRESSION ANXIETY STRESS SCALE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIFE STRESS; LIFESTYLE MODIFICATION; MALE; MEDICAL HISTORY; MIDDLE AGED; MOTIVATIONAL ENHANCEMENT THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOTHERAPY; SELF REPORT; SMOKING HABIT; SOCIAL INTERACTION; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYMPTOM; TREATMENT OUTCOME; UNIVERSITY OF RHODE ISLAND CHANGE ASSESSMENT;

EID: 84891828754     PISSN: 10777229     EISSN: 1878187X     Source Type: Journal    
DOI: 10.1016/j.cbpra.2013.06.002     Document Type: Article

References (45)

1. Australian Institute of Health and Welfare 2010 National Drug Strategy Household Survey Report 2011, Australian Institute of Health and Welfare, Canberra.
2. Baylen C.A., Rosenberg H. A review of the acute subjective effects of MDMA/ecstasy. Addiction 2006, 101:1-15.
3. Bruno R., Matthews A.J., Topp L., Degenhardt L., Gomez R., Dunn M. Can the Severity of Dependence Scale be usefully applied to ecstasyα. Neuropsychobiology 2009, 60:137-147.
4. Burgess C., O'Donohoe A., Gill M. Agony and ecstasy: A review of MDMA effects and toxicity. European Psychiatry 2000, 15:287-294.
5. Carlson R.G., Falck R.S., McCaughan J.A., Siegal H.A. MDMA/Ecstasy use among young people in Ohio: Perceived risk and barriers to intervention. Journal of Psychoactive Drugs 2004, 36:181-189.
6. Cottler L.B., Leung K.S., Abdallah A.B. Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: A cross-national study. Addiction 2009, 104:1679-1690.
7. Motivation hypothesis casual chain analysis 2001, Vol. 8. National Institute on Alcohol Abuse and Alcoholism, Rockville, MD.
8. DiClemente C.C., Schlundt D., Gemmell L. Readiness and stages of change in addiction treatment. The American Journal on Addictions 2004, 13(2):103-119.
9. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. The American Journal of Psychiatry 2008, 165:179-187.
10. Erowid MDMA hangovers and week-after effects Retrieved January 6, 2013, from. http://www.erowid.org/chemicals/mdma/mdma_effects_hangover1.shtml.
11. Fals-Stewart W., O'Farrell T.J., Freitas T.T., McFarlin S.K., Rutigliano P. The Timeline Followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology 2000, 68:134-144.
12. Field C.A., Adinoff B., Harris T.R., Ball S.A., Carroll K.M. Construct, concurrent and predictive validty of the URICA: Data from two multisite clinical trials. Drug and Alcohol Dependence 2009, 101:115-123.
13. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W. Structured clinical interview for DSM-IV-TR Axis I Disorders 2002, Biometrics Research Department, New York.
14. Green A.R., Mechan A.O., Elliott M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacological Reviews 2003, 55:463-508.
15. Huang Y., Tang T., Lin C., Yen C. Effects of motivational enhancement therapy on readiness to change MDMA and methamphetamine use behaviors in Taiwanese adolescents. Substance Use & Misuse 2011, 46:411-416.
16. Jaehne E.J., Majumber I., Salem A., Irvine R.J. Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression. Addiction Biology 2010, 16:7-19.
17. Levy K.B., Wish E.D., Arria A.M. An in-depth qualitative examination of the ecstasy experience: Results of a focus group with ecstasy using college students. Substance Use & Misuse 2005, 40:1427-1441.
18. Lieb R., Schuetz C.G., Pfister H., von Sydow K., Wittchen H.U. Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug and Alcohol Dependence 2002, 68:195-207.
19. Lovibond S.H., Lovibond P.F. Manual for the Depression Anxiety Stress Scales 1995, The Psychology Foundation of Australia, Sydney.
20. Lundahl B.W., Kunz C., Brownell C., Tollefson D., Burke B.L. A meta-analyis of motivational interviewing: Twenty-five years of empirical studies. Research on Social Work Practice 2010, 20:137-160.
21. Magill M., Ray L.A. Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. Journal of Studies on Alcohol and Drugs 2009, 70:516-527.
22. Majumber I., White J.M., Irvine R.J. Antidepressant-like effects of ecstasy in subjects with a predisposition to depression. Addictive Behaviors 2012, 37:1189-1192.
23. Marsden J., Stillwell G., Barlow H., Boys A., Taylor C., Hunt N., Farrell M. An evaluation of a brief motivational intervention among young ecstasy and cocaine users: No effect on substance and alcohol use outcomes. Addiction 2006, 101:1014-1026.
24. Martin G., Copeland J. Brief intervention for regular ecstasy (MDMA) users: Pilot randomized trial of a check-up model. Journal of Substance Use 2010, 15:131-142.
25. McConnaughy E.A., Prochaska J.O., Velicer W.F. Stages of change in psychotherapy: Measurement and sample profiles. Psychotherapy: Theory, Research and Practice 1983, 20:368-375.
26. Miller W.R. Motivational interviewing for problem drinkers. Behavioural Psychotherapy 1983, 11:147-172.
27. Miller W.R., Rollnick S. Motivational interviewing: Preparing people for change 2002, The Guilford Press, New York, NY.
28. Montoya A.G., Sorrention R., Lukas S.E., Price B.H. Long-term neuropsychiatric consequences of 'ecstasy' (MDMA): A Review. Harvard Review of Psychiatry 2002, 10:212-220.
29. National Drug and Alcohol Research Centre Education Trust. Ecstasy: Facts and Fiction 2009, Retrieved from http://ndarc.med.unsw.edu.au/content/ndarc-education-trust-net. 2nd ed.
30. Nieuwenhuijsen K., de Boer A.G.E.M., Verbeek J.H.A.M., Block R.W.B., van Dijk F.J.H. The Depression Anxiety Stress Scales (DASS): Detecting anxiety disorder and depression in employees absent from work because of mental health problems. Occupational and Environmental Medicine 2003, 60(Suppl. 1):i77-i82.
31. Parrott A.C. MDMA and 5-HT neurotoxicity: The empirical evidence for its adverse effects in humans - no need for translation. British Journal of Pharmacology 2012, 166:1518-1520.
32. Project MATCH Research Group Matching alcoholism treatment to client heterogeneity: Project MATCH posttreatment drinking outcomes. Journal of Studies on Alcohol 1997, 58:7-29.
33. Rodgers J., Buchanan T., Pearson C., Parrott A.C., Ling J., Heffernan T., Scholey A.B. Differential experiences of the psychobiological sequele of ecstasy use: Quantative and qualitative data from an internet study. Journal of Psychopharmacology 2006, 20:437-446.
34. Sindicich N., Burns L. Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2011, NDARC, Sydney.
35. Sindicich N., Burns L. Australian trends in ecstasy and related drug markets 2011. Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2012, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
36. Sobell L.C., Sobell M.C. Timeline Followback: A calendar method for assessing alcohol and drug use 1996, Addiction Research Foundation, Toronto, Ontario.
37. Steinkellner T., Freissmuth M., Sitte H.H., Montgomery T. The ugly side of amphetamines: Short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biological Chemistry Hoppe-Seyler 2011, 392:103-115.
38. The HABITS Lab at UMBC Readiness score for URICA Retrieved July 24, 2012, from. http://www.umbc.edu/psyc/habits/content/ttm_measures/urica/readiness.html.
39. Topp L., Hall W., Hando J. Is there a dependence syndrome for Ecstasyα 1997, Sydney, National Drug and Alcohol Research Centre (NDARC).
40. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: Patterns of use and associated harm. Drug and Alcohol Dependence 1999, 55:105-115.
41. United Nations Office on Drugs and Crime World Drug Report 2011 2011, United Nations, Vienna.
42. Verheyden S.L., Maidment R., Curran H.V. Quitting ecstasy: An investigation of why people stop taking the drug and their subsequent mental health. Journal of Psychopharmacology 2003, 17:371-378.
43. Vuori E., Henry J.A., Ojanpera I., Nieminen R., Savolainen T., Wahlsten P., Jantti M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003, 98:365-368.
44. World Health Organization Composite International Diagnostic Interview (CIDI) Core Version 2.1, 12month version 1997, World Health Organization, Geneva.
45. Zanarini M.C., Skodol A.E., Bender D., Dolan R., Sanislow C., Schaefer E., Morey L.C., Grilo C.M., Shea M.T., McGlashan T.H., Gunderson J.G. The Collaborative Longitudinal Personality Disorders Study: Reliability of axis I and II diagnoses. Journal of Personality Disorders 2000, 14:291-299.